Citations

Showing 10 of 108104 citations.

Intraarterial papaverine for relief of catheter‐induced peripheral arterial vasospasm during pediatric cardiac surgery: A randomized double‐blind controlled trial
Gautam, Nischal K. , Griffin, Evelyn , Hubbard, Richard , Pawelek, Olga, Edmonds, Kayla, Rydalch, Eric, Zhang, Xu , Sharma, Sahithi , Hoffmann, Cassandra

Mayo Clinic

Pediatric Anesthesia | March 19, 2022 | Volume: 32 | Issue: 6 | Pages: 764-771

10.1111/pan.14442 | PMID 35304932 Get It

AbstractBackgroundMaintaining the patency of peripheral arterial lines in pediatric patients during surgery can be challenging due to multiple factors, and catheter‐related arterial vasospasm is a potentially modifiable cause. Papaverine, a potent vasodilator, improves arterial line patency when used as a continuous infusion in the pediatric intensive care setting, but this method is not convenient during surgery.AimExtrapolating from the benefit seen in the intensive care unit, the authors hypothesize that a small‐volume intraarterial bolus of papaverine immediately after arterial line placement will reduce vasospasm‐related arterial line malfunction.MethodsThis was a prospective, randomized, double‐blind study. Patients less than 17 years of age undergoing cardiac surgery were enrolled. Patients were randomized into the heparin or papaverine groups. Immediately after arterial line insertion, an intraarterial bolus of heparin (2 units/ml, 1 ml) or papaverine (0.12 mg/ml, 1 ml) was administered (T1, Figure 1). An optimal waveform was defined as the ease of aspirating a standardized blood sample within 30 s, absence of cavitation when sampling, absence of color change at the catheter site during injection, and presence of a dicrotic notch. The primary outcome evaluated was the presence of an optimal arterial waveform at 5 min after the first randomized dose (T1 + 5 min). The secondary outcomes were the presence of optimal arterial waveform an hour after the first dose and the ability of papaverine to rescue suboptimal waveforms.ResultsA total of 100 patients were enrolled in the study. Twelve patients were excluded from the analysis. Complete datasets after randomization were available in 88 patients (heparin group, n = 46; papaverine group, n = 42). At baseline, groups were similar for age, weight, arterial vessel size, and arterial line patency. At T1 + 5 min, an improvement in the waveform characteristics was observed in the papaverine group (heparin,39% [8/46] vs. papaverine, 64% [27/42]; p = .02; odds ratio, 2.8; 95% CI, 1.2 to 6.6, Figure 3, Table 2). At the end of 1 h, both groups showed continued improvement in arterial line patency. After the second dose, a higher number of patients in the heparin group had suboptimal waveforms and were treated with papaverine (heparin,37% [17/46] vs. papaverine,17% [7/42], p = .05). Patients in the heparin group treated with papaverine showed significant improvement in patency (13/17 vs. 3/7, p = .01). No serious adverse events were reported.ConclusionsIn pediatric patients, papaverine injection immediately after peripheral arterial catheter placement was associated with relief of vasospasm and improved initial arterial line patency. Further, papaverine can be used as a rescue to improve and maintain arterial line patency.
Alzheimer's disease and related dementias and heart failure: A community study
Manemann, Sheila M., Weston, Susan A., Jiang, Ruoxiang , Roger, Véronique L. , St Sauver, Jennifer, Bielinski, Suzette J. , Knopman, David S. , Sauver, Jennifer L. St. , Chamberlain, Alanna M.

Mayo Clinic

Journal of the American Geriatrics Society | March 19, 2022 | Volume: 70 | Issue: 6 | Pages: 1664-1672

10.1111/jgs.17752 | PMID 35304739 Get It

Abstract Background Cognitive function is essential to effective self‐management of heart failure (HF). Alzheimer's disease and Alzheimer's disease‐related dementias (AD/ADRD) can coexist with HF, but its exact prevalence and impact on health care utilization and death are not well defined. Methods Residents from 7 southeast Minnesota counties with a first‐ever diagnosis code for HF between January 1, 2013 and December 31, 2018 were identified. Clinically diagnosed AD/ADRD was ascertained using the Centers for Medicare and Medicaid (CMS) Chronic Conditions Data Warehouse algorithm. Patients were followed through March 31, 2020. Cox and Andersen‐Gill models were used to examine associations between AD/ADRD (before and after HF) and death and hospitalizations, respectively. Results Among 6336 patients with HF (mean age [SD] 75 years [14], 48% female), 644 (10%) carried a diagnosis of AD/ADRD at index HF diagnosis. The 3‐year cumulative incidence of AD/ADRD after HF diagnosis was 17%. During follow‐up (mean [SD] 3.2 [1.9] years), 2618 deaths and 15,475 hospitalizations occurred. After adjustment, patients with AD/ADRD before HF had nearly a 2.7 times increased risk of death, but no increased risk of hospitalization compared to those without AD/ADRD. When AD/ADRD was diagnosed after the index HF date, patients experienced a 3.7 times increased risk of death and a 73% increased risk of hospitalization compared to those who remain free of AD/ADRD. Conclusions In a large, community cohort of patients with incident HF, the burden of AD/ADRD is quite high as more than one‐fourth of patients with HF received a diagnosis of AD/ADRD either before or after HF diagnosis. AD/ADRD markedly increases the risk of adverse outcomes in HF underscoring the need for future studies focused on holistic approaches to improve outcomes.
Lipoproteins in the Central Nervous System: From Biology to Pathobiology
Raulin, Ana‐Caroline , Martens, Yuka A. , Bu, Guojun , Bu, Guojun , Raulin, Ana-Caroline

Mayo Clinic

Annual Review of Biochemistry | March 19, 2022 | Volume: 91 | Issue: 1 | Pages: 731-759

10.1146/annurev-biochem-032620-104801 | PMID 35303786 Get It

The brain, as one of the most lipid-rich organs, heavily relies on lipid transport and distribution to maintain homeostasis and neuronal function. Lipid transport mediated by lipoprotein particles, which are complex structures composed of apolipoproteins and lipids, has been thoroughly characterized in the periphery. Although lipoproteins in the central nervous system (CNS) were reported over half a century ago, the identification of APOE4 as the strongest genetic risk factor for Alzheimer's disease has accelerated investigation of the biology and pathobiology of lipoproteins in the CNS. This review provides an overview of the different components of lipoprotein particles, in particular apolipoproteins, and their involvements in both physiological functions and pathological mechanisms in the CNS.
Left Atrial Volumetric/Mechanical Coupling Index
Essayagh, Benjamin , Nistri, Stefano , Maalouf, Joseph , Rossi, Andrea , Thapa, Prabin , Michelena, Héctor I. , Enriquez‐Sarano, Maurice , Benfari, Giovanni , Michelena, Hector I , Enriquez-Sarano, Maurice , Benfari, Giovanni , Essayagh, Benjamin , Nistri, Stefano

Mayo Clinic

Circulation: Cardiovascular Imaging | March 19, 2022 | Volume: 14 | Issue: 1 | Pages: No page available

10.1161/circimaging.120.011608 | PMID 33463368 Get It

Background: Left atrial assessment is complex, particularly in heart failure with reduced ejection fraction due to interactions with functional mitral regurgitation (FMR). Pilot data suggest that left atrial volumetric/mechanical coupling index (LACI) may be useful, but large outcome data are lacking. Methods: We enrolled a comprehensively characterized cohort of patients in sinus rhythm with heart failure with reduced ejection fraction diagnosis at Mayo Clinic from 2007 to 2011. Routinely measured left atrial volume index and tissue-doppler-imaging a’ allowed LACI calculation as (left atrial volume index)/(tissue-doppler-imaging a’). Survival was the outcome measured. Results: The cohort’s 4196 patients (69 [58–77] years, ejection fraction 40 [31–45]%) had mild FMR in 1505 and moderate-severe FMR in 1068. LACI was overall 5.06 (3.50–8.10) and increased with each FMR grade (3.86 [2.94–5.29] without FMR, 5.38 [3.80–8.02] with mild, 5.45 [1.49–8.07] with moderate/severe FMR; P <0.0001). At diagnosis, higher LACI was independently determined by more severe FMR and by higher left ventricular mass index, lower ejection fraction, higher E/e’, and lower glomerular filtration rate (all P <0.0001). During follow-up 1588 (38%) patients died. In spline modeling, excess mortality appeared around LACI=6 and steeply increased thereafter (5-year survival 72±1% with LACI<6 and 49±2% with LACI ≥6, P <0.0001). Multivariable comprehensive adjustment showed LACI strong association with excess mortality (adjusted hazard ratio, 1.41 [1.23–1.61], P <0.0001 for LACI ≥6). Independent link to mortality persistent across FMR grades (adjusted hazard ratio, 1.45 [1.13–1.86], P =0.004 without FMR, 1.42 [1.16–1.77], P =0.0008 with mild FMR, and 1.38 [1.01–1.66], P =0.04 with moderate/severe FMR) without interaction ( P =0.3). LACI independent impact on outcome was incremental to that of left atrial volume index, tissue-doppler-imaging a’, or any other characteristic including the Meta-Analysis Global Group in Chronic-score (least significant P =0.02). Conclusions: In this large cohort, left atrial volumetric/mechanical coupling measured by LACI in routine practice integrates the influence of several morphological/hemodynamic determinants but displays progressive deterioration with increasing FMR severity in heart failure with reduced ejection fraction. About outcome, higher LACI is strongly, independently, and incrementally associated with excess mortality, irrespective of FMR grade and in all subsets. Hence, LACI is a novel and critical measure in heart failure with reduced ejection fraction, quantifiable in routine practice, which should be integrated in prognostication and decision-making.
Arthroscopic Remplissage Using Knotless, All‐Suture Anchors
McQuivey, Kade S. , Brinkman, Joseph C. , Tummala, Sailesh V. , Shaha, James S., Tokish, John M. , Tummala, Sailesh V

Mayo Clinic

Arthroscopy Techniques | March 19, 2022 | Volume: 11 | Issue: 4 | Pages: No page available

10.1016/j.eats.2021.12.015 | PMID 35493050 Get It

Abstract Glenohumeral bone loss is a significant risk factor for recurrent instability after shoulder dislocation. The Hill‐Sachs lesion is an osseous defect of the posterior humeral head that is commonly recognized after anterior shoulder dislocation. Several procedures exist to address humeral‐sided bone loss, including soft tissue filling procedures, osteoarticular allografts, bone plugs, rotation osteotomies, and humeral head replacements. However, among the most common of these procedures is the arthroscopic remplissage. This technique involves capsulotenodesis of the posterior shoulder capsule and infraspinatus tendon into a Hill‐Sachs lesion. Previously described techniques use knotted suture anchors. In this report, we describe a modified technique for remplissage using knotless, all‐suture anchors to perform capsulotenodesis of a Hill‐Sachs lesion. Benefits of this technique include a single skin incision, improved bone preservation, and easier facilitation of revision surgery if required. Technique Video video See video under supplementary data.
Changes in Cigarette Smoking Behavior in Cancer Survivors During Diagnosis and Treatment
Jose, Thulasee , Schroeder, Darrell R. , Warner, David O. , Warner, David O , Jose, Thulasee , Schroeder, Darrell

Mayo Clinic

Nicotine & Tobacco Research | March 18, 2022 | Volume: 24 | Issue: 10 | Pages: 1581-1588

10.1093/ntr/ntac072 | PMID 35311999 Get It

Abstract Introduction Continued cigarette smoking is a critical determinant of outcome in oncology patients, but how the separate events of cancer diagnosis, cancer treatment, and completion of treatment affect smoking behavior in cancer survivors is unknown. This study described such changes, hypothesizing that they would be more pronounced for smoking-related cancers. Methods The Cancer Patient Tobacco Use Questionnaire (CTUQ) was sent to every cancer patient ≥ 18 y old scheduled for outpatient visits at the Mayo Clinic Cancer Center with a current or former history of tobacco use. Results From September 2019 to September 2020, 33,831 patients received the CTUQ, and 20,818 (62%) responded. Of the 3007 current smokers analyzed, 34% quit at diagnosis; those with smoking-related cancers were more likely to quit (40% vs. 29%, respectively, p &lt; .001). Among those who did not quit at diagnosis, 31% quit after starting cancer treatment, and those with smoking-related cancers were more likely to quit (35% and 28%, respectively, p = .002) Among those who had quit before the completion of treatment, 13% resumed smoking after treatment ended. In multivariable analysis, patients with smoking-related cancers were more likely to report 30-d point prevalence abstinence from pre-diagnosis to the completion of treatment (adjusted OR 1.98 [95% CI 1.65, 2.36], p &lt; .001). Conclusions Both cancer diagnosis and treatment prompt smoking abstinence, with most maintaining abstinence after treatment is completed. Those with smoking-related cancers are more likely to quit. These results emphasize the need to provide access to tobacco treatment services that can further support cancer patients who smoke. Implications Approximately one-third of cancer patients who smoke quit smoking at the time of diagnosis, an additional one-third of patients who had not yet quit did so at the initiation of treatment, and most sustained this abstinence after treatment completion. Patients with smoking-related cancers are more likely to quit. Thus, there are multiple opportunities within the cancer care continuum to intervene and support quit attempts or continued abstinence.
Hippocampal Subfields in Mild Cognitive Impairment: Associations with Objective and Informant-Report of Memory Function
O’Shea, Deirdre , Wit, Liselotte De , Tanner, Jared J. , Amofa, Priscilla , Pérez-Lao, Ámbar , Levy, Shellie‐Anne , Chandler, Melanie , De Wit, Liselotte , Kurasz, Andrea M. , Smith, Glenn E.

Mayo Clinic

Archives of Clinical Neuropsychology | March 18, 2022 | Volume: 37 | Issue: 7 | Pages: 1502-1514

10.1093/arclin/acac018 | PMID 35443280 Get It

AbstractBackgroundEvidence suggests that select hippocampal subfields are implicated in the initial stages of Alzheimer’s disease (AD) and are selectively involved in objective memory. Less is known whether subfields are associated with informant-reported memory difficulties of individuals with a diagnosis of mild cognitive impairment (MCI).MethodData from 56 participants with a diagnosis of amnestic MCI were included in the present study. To test whether FreeSurfer derived hippocampal subfields (CA1–4, subiculum, presubiculum, and dentate gyrus) were associated with objective (learning and delayed recall) and informant-reports of memory difficulties, we used multiple linear regression analysis. Subfields were adjusted for total intracranial volume, and age, sex, and years of education were included as covariates in all models.ResultsLarger presubiculum, subiculum, and CA4/dentate gyrus volumes were associated with higher delayed recall scores, and larger subiculum and CA4/dentate gyrus volumes were associated with fewer informant-reports of memory difficulties. There were no statistically significant associations between subfields and learning scores.DiscussionFindings from the present study support the idea that difficulties with memory-dependent everyday tasks in older adults with MCI may signal a neurodegenerative process while increasing understanding of subfields correlates of these memory-specific functional difficulties. Continued investigations into identifying patterns of subfield atrophy in AD may aid early identification of those at higher risk of dementia conversion while advancing precision medicine.
Allergic airway recall responses require IL-9 from resident memory CD4 + T cells
Ulrich, Benjamin J. , Kharwadkar, Rakshin , Chu, Michelle , Pajulas, Abigail , Muralidharan, Charanya , Koh, Byunghee , Fu, Yongyao , Gao, Hongyu , Hayes, Tristan , Zhou, Hongming , Goplen, Nick P., Nelson, Andrew S. , Turner, Matthew J. , Licona-Limón, Paula , Kaplan, Mark H. , Hayes, Tristan A , Zhou, Hong-Ming , Goplen, Nicholas P , Liu, Yunlong , Linnemann, Amelia K , Turner, Matthew J , Licona-Limón, Paula , Flavell, Richard A , Sun, Jie , Kaplan, Mark H , Flavell, Richard A. , Sun, Jie

Mayo Clinic

Science Immunology | March 18, 2022 | Volume: 7 | Issue: 69 | Pages: No page available

10.1126/sciimmunol.abg9296 | PMID 35302861 Get It

Asthma is a chronic inflammatory lung disease with intermittent flares predominately mediated through memory T cells. Yet, the identity of long-term memory cells that mediate allergic recall responses is not well defined. In this report, using a mouse model of chronic allergen exposure followed by an allergen-free rest period, we characterized a subpopulation of CD4 + T cells that secreted IL-9 as an obligate effector cytokine. IL-9–secreting cells had a resident memory T cell phenotype, and blocking IL-9 during a recall challenge or deleting IL-9 from T cells significantly diminished airway inflammation and airway hyperreactivity. T cells secreted IL-9 in an allergen recall–specific manner, and secretion was amplified by IL-33. Using scRNA-seq and scATAC-seq, we defined the cellular identity of a distinct population of T cells with a proallergic cytokine pattern. Thus, in a recall model of allergic airway inflammation, IL-9 secretion from a multicytokine-producing CD4 + T cell population was required for an allergen recall response.
The role of preoperative optimization of the nutritional status on the improvement of short‐term outcomes after liver transplantation? A review of the literature and expert panel recommendations
Victor, David W. , Towey, Jennifer , Spiro, Michael , Burra, Patrizia , Group, the ERAS4OLT.org Working, Zanetto, Alberto , Montaño‐Loza, Aldo J. , Heimbach, Julie K. , Raptis, Dimitri , Group, the ERAS4OLT.org Working, Tinguely, Pascale

Mayo Clinic

Clinical Transplantation | March 18, 2022 | Volume: 36 | Issue: 10 | Pages: No page available

10.1111/ctr.14647 | PMID 35303370 Get It

AbstractBackgroundMalnutrition is a known risk factor for postoperative morbidity and mortality in patients awaiting liver transplantation (LT). Malnutrition is a potentially reversible risk factor, though there are no clear guidelines on the best mechanism for an improvement. It also remains unclear if preoperative nutritional interventions have benefits to post‐transplant outcomes for transplant recipients.ObjectivesPrimary objective: To identify if preoperative optimization of nutritional status is associated with improved short‐term outcomes after LT. Secondary Objectives: To determine if preoperative improvement of malnutrition improves short‐term outcomes after LT, as well as if weight loss in obese patients affects short‐term outcomes after LT.Data sourcesOvid MEDLINE, Embase, Scopus, Google Scholar, and Cochrane Central.MethodsSystematic review following PRISMA guidelines and recommendations using the GRADE approach derived from an international expert panel. POSPERO Protocol ID: CRD42021237450Results3851 records were identified in searching the databases, 3843 records were excluded by not fulfilling eligibility criteria. Seven full‐text articles were included for the final analysis of which three were randomized controlled trials, one was prospective observational studies, and three were retrospective observational studies. No appreciable difference in mortality, post‐transplant complication rate was noted across the studies. Length of stay (LOS) was noted to be shorter in two observational studies of Vitamin D deficiency in liver transplant patients.ConclusionsWe have made a weak recommendation supporting pre‐transplant nutritional supplementation due to possible benefit in reducing LOS as well as the lack of harm (Quality of Evidence low | Grade of Recommendation; Weak). No effective conclusions were reached for the secondary objectives due to the conflicting evidence.
Early administration of COVID‐19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy
Huang, Yin , Villa, Carlos H. , Whitaker, Barbee , Anderson, Steven A. , Verdun, Nicole, Joyner, Michael J. , Wright, Scott, Carter, Rickey E. , Hung, Deborah T. , Homer, Mary J. , Hoffman, Corey M., Lauer, Michael S. , Wright, Scott R, Marks, Peter , Carter, Rickey E , Joyner, Michael J , Belov, Artur , Forshee, Richard A. , Eder, Anne F. , Wright, Scott R.

Mayo Clinic

American Journal of Hematology | March 18, 2022 | Volume: 97 | Issue: 6 | Pages: 770-779

10.1002/ajh.26531 | PMID 35303377 Get It

AbstractThe efficacy of COVID‐19 convalescent plasma (CCP) as a treatment for hospitalized patients with COVID‐19 remains somewhat controversial; however, many studies have not evaluated CCP documented to have high neutralizing antibody titer by a highly accurate assay. To evaluate the correlation of the administration of CCP with titer determined by a live viral neutralization assay with 7‐ and 28‐day death rates during hospitalization, a total of 23 118 patients receiving a single unit of CCP were stratified into two groups: those receiving high titer CCP (>250 50% inhibitory dilution, ID50; n = 13 636) or low titer CCP (≤250 ID50; n = 9482). Multivariable Cox regression was performed to assess risk factors. Non‐intubated patients who were transfused with high titer CCP showed 1.1% and 1.7% absolute reductions in overall 7‐ and 28‐day death rates, respectively, compared to those non‐intubated patients receiving low titer CCP. No benefit of CCP was observed in intubated patients. The relative benefit of high titer CCP was confirmed in multivariable Cox regression. Administration of CCP with high titer antibody content determined by live viral neutralization assay to non‐intubated patients is associated with modest clinical efficacy. Although shown to be only of modest clinical benefit, CCP may play a role in the future should viral variants develop that are not neutralized by other available therapeutics.